News
Regeneron: Der Kampf um globale Gleichheit im Pharmasektor
Regeneron: Der Kampf um globale Gleichheit im Pharmasektor
Regeneron: Der Kampf um globale Gleichheit im Pharmasektor
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in
Johnson & Johnson Stock: Court Setback Triggers Financial Shift
Johnson & Johnson (J&J) faces a significant legal defeat as a US bankruptcy court in Texas rejected its subsidiary Red River Talc LLC's proposed settlement plan. This plan, valued at approximately
Johnson & Johnson Stock: Court Setback Triggers Financial Shift
Johnson & Johnson (J&J) faces a significant legal defeat as a US bankruptcy court in Texas rejected its subsidiary Red River Talc LLC's proposed settlement plan. This plan, valued at approximately
Rückschlag für Impfstoffaktien nach Rücktritt bei der FDA
Rückschlag für Impfstoffaktien nach Rücktritt bei der FDA
Zimmer Biomet Stock: Dividend Payout Set for March 2025
Zimmer Biomet Holdings, a leading medical technology manufacturer specializing in orthopedics, has announced a dividend distribution of $0.24 per share scheduled for late March 2025. This payment
Which Healthcare Stock Is the Best Buy Right Now?
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see
Draegerwerk Stock: Strong EBIT Growth Despite Market Challenges
Draegerwerk AG & Co. KGaA has reported positive results for the 2024 fiscal year despite difficult market conditions. The Lübeck-based medical and safety technology manufacturer achieved a 3.4
Eli Lilly Stock: Cholesterol Drug Shows Breakthrough Results
Eli Lilly's experimental drug Lepodisiran has delivered impressive results in Phase 2 clinical trials, reducing a genetic risk factor for heart disease by nearly 94 percent. The drug targets
Sanofi Stock: FDA Approves Breakthrough Hemophilia Treatment
Sanofi has received FDA approval for Qfitlia, its innovative hemophilia therapy that represents the first antithrombin-lowering treatment for hemophilia A or B patients with or without inhibitors
Sanofi Stock: FDA Approves Breakthrough Hemophilia Treatment
Sanofi has received FDA approval for Qfitlia, its innovative hemophilia therapy that represents the first antithrombin-lowering treatment for hemophilia A or B patients with or without inhibitors
Sanofi Stock: FDA Approves Breakthrough Hemophilia Treatment
Sanofi has received FDA approval for Qfitlia, its innovative hemophilia therapy that represents the first antithrombin-lowering treatment for hemophilia A or B patients with or without inhibitors
Abbott Laboratories Stock: CE Mark Boosts Cardiac Treatment Innovation
Abbott Laboratories recently experienced a significant upward breakthrough after receiving CE marking for its innovative Volt PFA system, designed to treat atrial fibrillation. This heart rhythm
Pfizer Stock: Probe Into COVID Vaccine Timing Claims
Pfizer shares are facing significant pressure following reports that Manhattan federal prosecutors are investigating serious allegations. The inquiry centers on claims made by British pharmaceutical
Pfizer Stock: Probe Into COVID Vaccine Timing Claims
Pfizer shares are facing significant pressure following reports that Manhattan federal prosecutors are investigating serious allegations. The inquiry centers on claims made by British pharmaceutical
Eli Lilly Stock: Outpaces Novo Nordisk in Obesity Market
Eli Lilly's stock has demonstrated remarkable resilience this year, gaining approximately 6% while Danish competitor Novo Nordisk faced significant losses. This divergence in performance reflects a
EQS-News: Sartorius AG – Beschlüsse der Hauptversammlung
EQS-News: Sartorius AG – Beschlüsse der Hauptversammlung
Santhera schlägt Dr. Melanie Rolli als neues Mitglied des Verwaltungsrats vor
«Ad hoc-Mitteilung gemäss Art. 53 KR»
Pratteln, Schweiz, 27. März 2025 - Santhera Pharmaceuticals (SIX: SANN) schlägt der kommenden Generalversammlung vom 20. Mai 2025 die Wahl von Dr. Melanie
EQS-News: Eckert & Ziegler: Rekordjahr 2024 mit neuen Höchstmarken
EQS-News: Eckert & Ziegler: Rekordjahr 2024 mit neuen Höchstmarken